EMEA-002472-PIP03-22-M01 - paediatric investigation plan

Beremagene geperpavec

Key facts

• Active substance:
  Beremagene geperpavec
• Therapeutic area:
  Dermatology
• Decision number:
  P/0249/2023
• PIP number:
  EMEA-002472-PIP03-22-M01
• Pharmaceutical form(s):
  Gel
• Condition(s) / indication(s):
  Treatment of dystrophic epidermolysis bullosa
• Route(s) of administration:
  Topical use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  05/07/2023
• Compliance check done:
  No

Decision

P/0249/2023 : EMA decision of 5 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03-22-M01)

Reference Number: EMA/289384/2023